Sacral neuromodulation tined lead migration rate at 5 years post-implant

Tomas L. Griebling, University of Kansas, Kansas City, KS, Jeffrey Mangel, MetroHealth Medical Center, Cleveland, OH, Jason Bennett, Female Pelvic Medicine, Grand Rapids, MI, Craig Comiter, Stanford University, Stanford, CA, Samuel Zylstra, Milford Regional Medical Center, Erin Bird, Scott and White Healthcare, Temple, TX, Suzette E. Sutherland, University of Washington, Seattle, WA, Daniel Cullin, University of Oklahoma, Oklahoma City, OK, Karen Noblett, University of California, Riverside, CA, Kellie Chase Berg, Medtronic, Minneapolis, MN, Fangyu Kan, Medtronic, Minneapolis, MN, Steven Siegel, Metro Urology, Woodbury, MN

To evaluate the cumulative tined lead migration rate at 5 years after InterStim™ implant in subjects with overactive bladder (OAB).

Background

The International Continence Society (ICS) Guidelines recommend sacral neuromodulation (SNM) as specialized treatment for idiopathic overactive bladder (OAB). SNM provides a means to interact with the neural system that controls effector organs and muscles innervated by the sacral nerves in the pelvic region. The InterStim® system provides SNM through an implantable neurostimulator that delivers electrical stimulation via a lead placed close to the sacral nerves.

InSite is a prospective, multicenter post-approval study. Subjects with bothersome symptoms of overactive bladder (OAB) including urinary urge incontinence (UI) or urgency-frequency (UF), who had not exhausted all medication options (failed at least 1 anticholinergic medication and had at least 1 medication not tried) were included.

Improvements have been made in the tined lead design and related implant technique since the original InterStim post-approval study.

In this current large, multicenter study a low and acceptable lead migration adverse event rate has been demonstrated.

Study Design and Methods

Subjects completed test stimulation with an external neurostimulator and if successful went on to receive the full InterStim system implant. Implanted subjects were followed at 3, 6, 12, and 24 months, and then annually to 5 years post-implant. Study approval was given by institutional review boards and all subjects provided informed consent.

Therapeutic success was defined as a UI or UF response; for UI as a ≥ 50% improvement in average leaks/day, for UF as a ≥ 50% improvement in voids/day or a return to normal voiding frequency (<8 voids/day) on a 3-day consecutive voiding diary.

Adverse events including lead migration/dislodgment were collected at scheduled and unscheduled visits. Suspected tined lead migrations resulting in an adverse event of lead migration/dislodgement were included in the analysis. Months from implant of the full system to first adverse event of lead migration in each subject was the outcome metric, regardless of when the subject was implanted during the trial. Subjects that were lost-to-follow-up or did not experience this event prior to the end of their follow-up were treated as censored observations. Results are reported as a Kaplan-Meier estimate of the survival function at five years.

Of the 340 subjects who went through test stimulation, 272 were implanted. Demographics of implanted patients are listed in the Table.

<table>
<thead>
<tr>
<th>Demographics</th>
<th>All implanted (n=272)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender, female</td>
<td>91%</td>
</tr>
<tr>
<td>Race, white</td>
<td>89%</td>
</tr>
<tr>
<td>Mean age at implant (years)</td>
<td>57 ± 14</td>
</tr>
<tr>
<td>Mean duration of diagnosis at implant (years)</td>
<td>8 ± 10</td>
</tr>
<tr>
<td>Baseline leaks/day*</td>
<td>3.1 ± 2.7</td>
</tr>
<tr>
<td>Baseline voids/day*</td>
<td>12.6 ± 4.5</td>
</tr>
<tr>
<td>Median # of OAB medications tried prior to implant</td>
<td>2</td>
</tr>
</tbody>
</table>

+Plus-minus values are mean±SD. * Leaks and voids include only those subjects who qualified for UI (leaks) or UF (voids) at baseline. A subject could qualify for both.

- At 5-years, the lead migration adverse event rate was 5.9% (95% CI: 2.9% - 8.9%).
- A total of 17 lead migration adverse events occurred in 14 subjects on or after neurostimulator implant.
  - 11 subjects experienced 1 adverse event of lead migration which corresponds to 11 adverse events
  - 3 subjects experienced 2 such adverse events which correspond to 6 adverse events.
- Reprogramming was initially attempted in nine events. Eventually all leads were replaced.
- All events were resolved without sequelae.

Interpretation

A 5-year tined lead migration adverse rate of 5.9% is low. This rate is improved from the original InterStim post-approval study which indicated a lead migration adverse event rate of 9.3% at 5 years.

Conclusion

Improvements have been made in the tined lead design and related implant technique since the original InterStim post-approval study. In this current large, multicenter study a low and acceptable lead migration adverse event rate has been demonstrated.

This trial was sponsored by Medtronic, Inc.